Anti-Histone H3.3 G34W Rabbit Monoclonal Antibody [Clone RM263]; Histone H3.3 G34W Mutant; 31-1145-00-S; 31-1145-00-L; 31-1145-02

Key features and details

  • Uniprot: P84243
  • Gene ID: 8350
  • Host Species: Rabbit
  • Species Reactivity: Human
  • Concentration: N/A
  • Brand:
CAT.NO. : 31-1145-00
US$ Please choose
US$ Please choose
Trail, Bulk size or Custom requests Please contact us
Product Details
Product Details
Product NameAnti-Histone H3.3 G34W Rabbit Monoclonal Antibody, Clone RM263
Product DescriptionRabbit monoclonal to Histone H3.3 G34W; Histone H3.3 G34W Mutant
Catalog No.31-1145-00-S;
31-1145-00-L;
31-1145-02
Clone NameRM263
Product Data SheetAnti-Histone H3.3 G34W Mutant Rabbit Monoclonal Antibody Data Sheet RM263

Biotinylated Anti-Histone H3.3 G34W Mutant Rabbit Monoclonal Antibody Data Sheet RM263
SpecificityRM263 reacts to the Histone H3.3 G34W mutant. No cross reactivity with wild type Histone H3.3 .
ImmunogenA peptide corresponding to Histone H3.3 G34W mutant
ApplicationWestern Blot
ELISA
Immunohistochemistry
Chromatin IP
Species ReactivityAll
ConjugateNone
Intended UseResearch Use Only
.
Properties
FormLiquid
Storage InstructionsStore at -20.0°C
StabilityStable for 1 Year at -20.0°C from date of receipt
Storage Buffer50% Glycerol/PBS with 1% BSA and 0.09% sodium azide
Volume/Size100 µL;
400 µL;
Biotinylated 50 µL
PurityProtein A affinity purified from an animal origin–free culture supernatant
Clone TypeMonoclonal
IsotypeRabbit IgG
UsageWestern Blot: 1:125 – 1:500;
ELISA: 1:125 – 1:500;
IHC: 1:100 - 1:200.
References for Histone H3.3 G34W Mutant antibody [RM263]Gong L et al H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors. Histol Histopathol. (2021), 10.14670/HH-18-264. IHC; Human. Read more (PubMed: 33021329)

Khazaei S et al. H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone. Cancer Discov. (2020), 10.1158/2159-8290.CD-20-0461. WB, IHC, ChIP-seq; Human. Read more (PubMed: 32967858)

Yamaga K et al. Successful Treatment with Denosumab of a Giant Cell Tumor of Bone in the Iliac Bone of an 84-Year-Old Man. Yonago Acta Med. (2020), 10.33160/yam.2020.08.013. IHC; Human. Read more (PubMed: 32884443)

Shibuya I et al. Immunohistochemical Analysis of the Distribution of RANKL-Expressing Cells and the Expression of Osteoclast-Related Markers in Giant Cell Tumor of Bone. Journal of Hard Tissue Biology. (2020), 10.2485/jhtb.29.137. IHC; Human. Read more (J-STAGE)

Papke D J et al. Clinicopathologic characterization of malignant chondroblastoma: a neoplasm with locally aggressive behavior and metastatic potential that closely mimics chondroblastoma-like osteosarcoma. Mod Pathol. (2020), 10.1038/s41379-020-0604-2. IHC; Human. Read more (PubMed: 32601382)

Ud Din Net al. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone. Int J Surg Pathol. (2020), 10.1177/1066896920920716. IHC; Human. Read more (PubMed: 32429739)

Metovic J et al. Prognostic role of PD‑L1 and immune‑related gene expression profiles in giant cell tumors of bone. Cancer Immunol Immunother. (2020), 10.1007/s00262-020-02594-9. IHC; Human. Read more (PubMed: 32377818)

Fritchie K J et al. Xanthogranulomatous epithelial tumor: report of 6 cases of a novel, potentially deceptive lesion with a predilection for young women. Mod Pathol. (2020), 10.1038/s41379-020-0562-8. IHC; Human. Read more (PubMed: 32415263)

Brčić I et al. Giant Cell Tumor of Bone With Cartilage Matrix: A Clinicopathologic Study of 17 Cases. Am J Surg Pathol. (2020), 10.1097/PAS.0000000000001446. IHC; Human. Read more (PubMed: 32412716)

Treffel M et al. Denosumab-treated Giant Cell Tumors of Bone: A Clinicopathologic Analysis of 35 Cases From the French Group of Bone Pathology. Am J Surg Pathol. (2020), 10.1097/PAS.0000000000001388. IHC-P (Dako Flex+Envision revelation system); Human. Read more (PubMed: 31651524)

Leinauer B et al. Giant Cell Tumor of Bone – new aspects, new problems. Osteologie. (2020), 10.1055/a-1083-8923. IHC; Human. Read more (Thieme)

Oliveira Filho S et al. Angiogenesis (WT1, CD31 and CD105) and mutation (Gene H3F3A) in central lesions of aggressive and non-aggressive giant cells. Dissertação (Mestrado em Odontologia). (2019), Universidade Federal de Goiás, Goiânia. IHC; Human. Read more (Dissertação)

Taniguchi Y et al. Anti-tumor Effects of Cyclolinopeptide on Giant-cell Tumor of the Bone. Anticancer Res. (2019), 10.21873/anticanres.13822. IF; Human. Read more (PubMed: 31704842)

Yoshida KI et al. Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone. Mod Pathol. (2019), 10.1038/s41379-019-0318-5. IHC; Human. Read more (PubMed: 31285528)

Venning VL et al. Poorly differentiated cutaneous squamous cell carcinoma with osteoclast¬like giant cell: A rare, aggressive variant. Clin Case Rep. (2019), 10.1002/ccr3.1955. IHC; Human. Read more (PubMed: 30847202)

Ito Y et al. Giant cell-rich osteosarcoma of the vertebra with murine double minute chromosome 2- and cyclin-dependent kinase 4-positive and histone H3F3A mutant p.Gly34Trp-negative immunophenotypes. Pathol Int. (2018), 10.1111/pin.12650. IHC; Human. Read more (PubMed: 29446514)

Shimizu J et al. Arthroscopic Resection for Benign Fibrous Histiocytoma in the Epiphysis of the Femur. Case Rep Orthop. (2018), 10.1155/2018/8030862. IHC; Human. Read more (PubMed: 30581643)

Li HR et al. USP6 gene rearrangement differentiates primary paranasal sinus solid aneurysmal bone cyst from other giant cell–rich lesions: report of a rare case. Hum Pathol. (2018), 10.1016/j.humpath.2017.11.018. IHC; Human. Read more (PubMed: 29217425)

Lindholm KE et al. Osteoclast-like giant cell rich carcinomas of the lung: a Clinicopathological, Immunohistochemical, and molecular study of three cases. Hum Pathol. (2019), 10.1016/j.humpath.2018.10.030. IHC; Human. Read more (PubMed: 30447297)

Lübbehüsen C et al. Characterization of Three Novel H3F3A-mutated Giant Cell Tumor Cell Lines and Targeting of Their Wee1 Pathway. Sci Rep. (2019), 10.1038/s41598-019-42611-1. IHC-P, WB; Human. Read more (PubMed: 31015476)

Fellenberg J et al. Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells. Cancer Lett. (2019), 10.1016/j.canlet.2019.02.001. IHC-P; Human. Read more (PubMed: 30742944)

Giesche, J. P et al. H3F3A mutated multicentric giant cell tumor of bone : A very rare primary bone disease. Pathologe. Springer Nature. (2018) 10.1007/s00292-018-0460-8. IHC-P; Human. Read more (PubMed: 30046846)

Lüke J. et al. New aspects on giant cell tumor of bone. Pathologe. Springer Nature. (2018) 10.1007/s00292-017-0391-9, IHC-P; Human. Read more (PubMed: 29110035)

Rehkamper J et al. Diagnostic tools in the differential diagnosis of giant cell-rich lesions of bone at biopsy. Oncotarget. (2018), 10.18632/oncotarget.25725. IHC-P; Human. Read more (PubMed: PMC6059026)

Tsukamoto Y et al. An extremely rare case of primary malignancy in giant cell tumor of bone, arising in the right femur and harboring H3F3A mutation. Pathol Res Pract. (2018) 10.1016/j.prp.2018.06.015. IHC-P; Human. Read more (PubMed: 29970305)

Patel V et al. Evaluation of H3.3 G34W expression in denosumabtreated giant cell tumor of bone and histologic mimics. Mod Pathol. (2018), USCAP 2018 Abstracts-Bone & Soft Tissue Pathology (45-120). IHC-P; Human. Read more (USCAP 2018 Abstracts: 101: PubMed: 29551782)

Schaefer IM et al. Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy. Cancer Cytopathol. (2018) 10.1002/cncy.22000. IHC-P; Human. Read more (PubMed: 29757500)

Scotto di Carlo F et al. The identification of H3F3A mutation in giant cell tumour of the clivus and the histological diagnostic algorithm of other clival lesions permit the differential diagnosis in this location. BMC Cancer (2018) 10.1186/s12885-018-4291-z. IHC-P; Human, IF-P; Human Read more (PubMed: 29609578)

Yamamoto H et al. Diagnostic utility of histone H3.3G34 W, G34R, and G34 V mutant-specific antibodies for giant cell tumors of bone. Human Pathology (2017) 10.1016/j.humpath.2017.11.020. IHC; Human. Read more (PubMed: 29241742)

Kato I et al. Giant Cell Tumours of Bone Treated with Denosumab: Histologic, Immunohistochemical, and H3F3A Mutation Analyses. Histopathology (2017) 10.1111/his.13448. IHC-P; Human. IF; Human. Read more (PubMed: 29206281)

Luke J et al. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant. Histopathology (2017) 10.1111/his.13190. IHC-P; Human. Read more (PubMed: 28211081)

Amary F et al. H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone. AM J Surg Pathol. (2017) 10.1097/PAS.0000000000000859. IHC-P; Human. Read more (PubMed: 28505000)

.
Product Images
Western

Western Blot analysis of cell lysates prepared from 293T, transfected with a DNA construct encoding G34W mutant or wild type proteins of Histone H3.3, using anti-Histone H3.3 G34W, Clone RM263.

Immunohistochemical

Immunohistochemical staining of formalin fixed and paraffin embedded 293T cells transfected with a DNA construct encoding Histone H3.3 G34W mutant or wild type, stained with anti-Histone H3.3 G34W, Clone RM263.

Immunohistochemical staining of Giant Cell Bone Tumor (GCBT) tissue sections using Anti-Histone H3.3 G34W antibody, Clone RM263.

Image courtesy of Adrienne Flanagan, Department of Histopathology, RONH, Stanmore, Middlesex, UK

Immunohistochemical staining of Giant Cell Bone Tumor (GCBT) tissue sections using Anti-Histone H3.3 G34W antibody. Clone RM263.

Image courtesy of Adrienne Flanagan, Department of Histopathology, RONH, Stanmore, Middlesex, UK

New Products
Get in touch with AREX
Name:*
Tel/Phone:*
Company:*
Email:*
Inquiry:
Captcha*
Submitting your email information means that you are willing to receive email information from AREX regarding technology, applications, products, and events. By clicking on the 'unsubscribe' button in the email or by contacting info@arexbio.com You can unsubscribe at any time by sending an email. Regarding your data usage information, please refer to our privacy policy.
© AREX 2024. All Rights Reserved. | 浙ICP备2024113709号-3 Sitemap